---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-023195"
form_type: "8-K"
ticker: "GTBP"
cik: "0000109657"
company_name: "GT Biopharma, Inc."
filed_at: "2024-06-07T23:59:59+00:00"
generated_at: "2026-06-01T05:28:07.744118+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# GT Biopharma appoints Alan Urban as CFO after terminating Manu Ohri

## Summary
- Manu Ohri's employment as CFO terminated effective June 3, 2024.
- Alan L. Urban appointed CFO; previously CFO at SRAX, Creek Road Miners, Research Solutions.
- Urban receives $375,000 base salary, up to 40% bonus, and equity award eligibility after 3 months.
- Employment agreement for one-year initial term with automatic renewal and severance terms.
- Urban reports to Executive Chairman & Interim CEO Michael Breen.

## SEC filing metadata
- accession: 0001493152-24-023195
- form_type: 8-K
- ticker: GTBP
- cik: 0000109657
- company_name: GT Biopharma, Inc.
- filed_at: 2024-06-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/109657/000149315224023195/0001493152-24-023195-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/109657/000149315224023195/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-023195
- JSON: https://secwatch.observer/filing/0001493152-24-023195.json
- Plain text: https://secwatch.observer/filing/0001493152-24-023195.txt

## Key facts
- Executive change
  Alan L. Urban was appointed as Chief Financial Officer at GT Biopharma, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: In connection with Mr. Ohri’s termination, on June 3, 2024, the Company has appointed Alan L. Urban as the Company’s Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/109657/000149315224023195/0001493152-24-023195-index.htm
- Executive change
  Manu Ohri was terminated as Chief Financial Officer at GT Biopharma, Inc..
  - Action: terminated
  - Role: Chief Financial Officer
  source text: On June 3, 2024, Manu Ohri’s employment as Chief Financial Officer at GT Biopharma, Inc. (the “Company”) was terminated.
  evidence_url: https://www.sec.gov/Archives/edgar/data/109657/000149315224023195/0001493152-24-023195-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.